Premium
Esketamine nasal spray offers rapid improvement in treatment‐resistant depression
Publication year - 2019
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30468
Subject(s) - medicine , nasal spray , antidepressant , depression (economics) , ketamine , treatment resistant depression , food and drug administration , placebo , drug , major depressive disorder , anesthesia , pharmacology , psychiatry , nasal administration , anxiety , alternative medicine , pathology , economics , macroeconomics , amygdala
Esketamine nasal spray in combination with a newly initiated antidepressant was more effective than a new antidepressant plus placebo in reducing depressive symptoms in patients with treatment‐resistant depression, a Phase 3 study has found. Esketamine, the S‐enantiomer of ketamine, recently received Food and Drug Administration (FDA) approval for treatment‐resistant depression in adults. Study results were published online May 21 in the American Journal of Psychiatry .